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Regulatory guidance documents clearly outline the requirements for demonstrating analytical 
comparability to support process changes and analytical similarity to support the approval of 
biosimilars. These include demonstration that process changes do not produce differences in 
product characteristics that might lead to an adverse impact on the safety or efficacy of the 
product1. For biosimilar products, a stepwise approach is required that starts with sponsors 
demonstrating that the product characteristics of the proposed biosimilar are either highly similar 
to that of the originator reference product or that any observed differences can be demonstrated 
to not impact the ability to leverage (or “conserve”) the safety and efficacy profile previously 
demonstrated by the originator2. Some product characteristics are however uniquely sensitive to 
small changes in process conditions, including but not limited to isoform charge distribution and 
glycan profiles. Moreover, as analytical methods continue to evolve, the ability to quantitatively 
detect small changes in these characteristics continues to improve. As such, every 
biotechnologist is faced with the question of what is comparable enough and/or what is similar 
enough. The author will review twenty years of regulatory feedback on these questions and 
discuss how regulatory agencies in the major markets have answered these same questions. 
 
1. FDA Guidance for Industry: “Comparability Protocols – Protein Drug Products and Biologics Products – 
Chemistry, Manufacturing and Controls Information” September 2003; ICH Guidance Q5E: “Comparability of 
Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process” 
2. FDA Guidance for Industry: “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product”, 
September 2012; CHMP: “Guideline on similar biologic medicinal products containing monoclonal antibodies – 
non-clinical and clinical issues”; 30MAY2012 
 
 
 
 
 
 
